Advertisement

Meta-Analysis Evaluating the Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Acute or Recently Decompensated Heart Failure

      Heart failure (HF) constitutes a major health problem worldwide, associated with significant morbidity and mortality.
      • Metra M
      • Teerlink JR.
      Heart failure.
      In addition, long-term outcomes of acute decompensated HF remain poor, with 1-year mortality reaching up to 40%.
      • Parikh KS
      • Sheng S
      • Hammill BG
      • Yancy CW
      • Fonarow GC
      • Hernandez AF
      • DeVore AD.
      Characteristics of acute heart failure hospitalizations based on presenting severity.
      Residual congestion and diuretic response represent main predictors of re-admission and all-cause death in survivors of an acute HF event.
      • Parikh KS
      • Sheng S
      • Hammill BG
      • Yancy CW
      • Fonarow GC
      • Hernandez AF
      • DeVore AD.
      Characteristics of acute heart failure hospitalizations based on presenting severity.
      Sodium-glucose co-transporter-2 (SGLT-2) inhibitors have been recently approved to treat HF with reduced left ventricular ejection fraction,
      • Parikh KS
      • Sheng S
      • Hammill BG
      • Yancy CW
      • Fonarow GC
      • Hernandez AF
      • DeVore AD.
      Characteristics of acute heart failure hospitalizations based on presenting severity.
      while empagliflozin is also recommended for patients with HF with preserved left ventricular ejection fraction, regardless of diabetes mellitus status at baseline.
      • Anker SD
      • Butler J
      • Filippatos G
      • Ferreira JP
      • Bocchi E
      • Böhm M
      • Brunner-La Rocca HP
      • Choi DJ
      • Chopra V
      • Chuquiure-Valenzuela E
      • Giannetti N
      • Gomez-Mesa JE
      • Janssens S
      • Januzzi JL
      • Gonzalez-Juanatey JR
      • Merkely B
      • Nicholls SJ
      • Perrone SV
      • Piña IL
      • Ponikowski P
      • Senni M
      • Sim D
      • Spinar J
      • Squire I
      • Taddei S
      • Tsutsui H
      • Verma S
      • Vinereanu D
      • Zhang J
      • Carson P
      • Lam CSP
      • Marx N
      • Zeller C
      • Sattar N
      • Jamal W
      • Schnaidt S
      • Schnee JM
      • Brueckmann M
      • Pocock SJ
      • Zannad F
      • Packer M
      EMPEROR-Preserved Trial Investigators
      Empagliflozin in heart failure with a preserved ejection fraction.
      However, the efficacy of SGLT-2 inhibitors in patients with acute decompensated HF remain unknown. Here, we sought to determine the cardiovascular efficacy of this drug class in the acute HF setting.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Metra M
        • Teerlink JR.
        Heart failure.
        Lancet. 2017; 390: 1981-1995
        • Parikh KS
        • Sheng S
        • Hammill BG
        • Yancy CW
        • Fonarow GC
        • Hernandez AF
        • DeVore AD.
        Characteristics of acute heart failure hospitalizations based on presenting severity.
        Circ Heart Fail. 2019; 12 (e005171)
        • Anker SD
        • Butler J
        • Filippatos G
        • Ferreira JP
        • Bocchi E
        • Böhm M
        • Brunner-La Rocca HP
        • Choi DJ
        • Chopra V
        • Chuquiure-Valenzuela E
        • Giannetti N
        • Gomez-Mesa JE
        • Janssens S
        • Januzzi JL
        • Gonzalez-Juanatey JR
        • Merkely B
        • Nicholls SJ
        • Perrone SV
        • Piña IL
        • Ponikowski P
        • Senni M
        • Sim D
        • Spinar J
        • Squire I
        • Taddei S
        • Tsutsui H
        • Verma S
        • Vinereanu D
        • Zhang J
        • Carson P
        • Lam CSP
        • Marx N
        • Zeller C
        • Sattar N
        • Jamal W
        • Schnaidt S
        • Schnee JM
        • Brueckmann M
        • Pocock SJ
        • Zannad F
        • Packer M
        • EMPEROR-Preserved Trial Investigators
        Empagliflozin in heart failure with a preserved ejection fraction.
        N Engl J Med. 2021; 385: 1451-1461
        • Damman K
        • Beusekamp JC
        • Boorsma EM
        • Swart HP
        • Smilde TDJ
        • Elvan A
        • van Eck JWM
        • Heerspink HJL
        • Voors AA.
        Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF).
        Eur J Heart Fail. 2020; 22: 713-722
      1. Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J, Ferreira JP, Nassif ME, Psotka MA, Tromp J, Borleffs CJW, Ma C, Comin-Colet J, Fu M, Janssens SP, Kiss RG, Mentz RJ, Sakata Y, Schirmer H, Schou M, Schulze PC, Spinarova L, Volterrani M, Wranicz JK, Zeymer U, Zieroth S, Brueckmann M, Blatchford JP, Salsali A, Ponikowski P. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial [published online February 20, 2022]. Nat Med doi:10.1038/s41591-021-01659-1

        • Bhatt DL
        • Szarek M
        • Steg PG
        • Cannon CP
        • Leiter LA
        • McGuire DK
        • Lewis JB
        • Riddle MC
        • Voors AA
        • Metra M
        • Lund LH
        • Komajda M
        • Testani JM
        • Wilcox CS
        • Ponikowski P
        • Lopes RD
        • Verma S
        • Lapuerta P
        • Pitt B
        SOLOIST-WHF Trial Investigators. Sotagliflozin in patients with diabetes and recent worsening heart failure.
        N Engl J Med. 2021; 384: 117-128